Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Routy

Showing results (31-40 of 126) with videos related to

Pageof 13
Sort By:
Nature Medicine|April 11, 2025
Impact of the ONCOBIOME network in cancer microbiome researchLaurence Zitvogel, Lisa Derosa, Bertrand Routy, et al.
Transfusion|March 25, 2025
Exchange transfusion and pre-filter apheresis dilution for hyperviscosity syndrome refractory to conventional therapeutic plasma exchange in a patient with IgA multiple myelomaAnthony Valin-Thorburn, Sara-Maude Desforges, Daniel Corsilli, et al.
Oncoimmunology|November 12, 2020
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockersSoleine Medjebar, Caroline Truntzer, Anaïs Perrichet, et al.
Oncotarget|November 29, 2017
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacyBrent A Williams, Arjun Datt Law, Bertrand Routy, et al.
Cancer Immunology Research|August 28, 2020
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung CancerTaiki Hakozaki, Corentin Richard, Arielle Elkrief, et al.
Cancers|February 27, 2026
Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung CancerRalph Saber, Marion Tonneau, Olivier Salko, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancerJulie Lecuelle, Laure Favier, Cléa Fraisse, et al.
Journal of Translational Medicine|January 10, 2024
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomicsSevinj Yolchuyeva, Leyla Ebrahimpour, Marion Tonneau, et al.
FEMS Microbiology Letters|June 22, 2023
Tractidigestivibacter montrealensis sp. nov., a new member of human gut microbiota isolated from a healthy volunteerMyriam Benlaïfaoui, Corentin Richard, Awa Diop, et al.
Nature Communications|February 27, 2023
Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomesCaroline Dufour, Corentin Richard, Marion Pardons, et al.
Pageof 13

Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Nature Medicine|April 11, 2025
Impact of the ONCOBIOME network in cancer microbiome researchLaurence Zitvogel, Lisa Derosa, Bertrand Routy, et al.
Transfusion|March 25, 2025
Exchange transfusion and pre-filter apheresis dilution for hyperviscosity syndrome refractory to conventional therapeutic plasma exchange in a patient with IgA multiple myelomaAnthony Valin-Thorburn, Sara-Maude Desforges, Daniel Corsilli, et al.
Oncoimmunology|November 12, 2020
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockersSoleine Medjebar, Caroline Truntzer, Anaïs Perrichet, et al.
Oncotarget|November 29, 2017
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacyBrent A Williams, Arjun Datt Law, Bertrand Routy, et al.
Cancer Immunology Research|August 28, 2020
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung CancerTaiki Hakozaki, Corentin Richard, Arielle Elkrief, et al.
Cancers|February 27, 2026
Multi-Institutional CT Scan-Based Radiomics for Predicting Tumor PD-L1 Expression in Patients with Advanced and Limited Non-Small Cell Lung CancerRalph Saber, Marion Tonneau, Olivier Salko, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancerJulie Lecuelle, Laure Favier, Cléa Fraisse, et al.
Journal of Translational Medicine|January 10, 2024
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomicsSevinj Yolchuyeva, Leyla Ebrahimpour, Marion Tonneau, et al.
FEMS Microbiology Letters|June 22, 2023
Tractidigestivibacter montrealensis sp. nov., a new member of human gut microbiota isolated from a healthy volunteerMyriam Benlaïfaoui, Corentin Richard, Awa Diop, et al.
Nature Communications|February 27, 2023
Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomesCaroline Dufour, Corentin Richard, Marion Pardons, et al.
Pageof 13